NCT02398929View on ClinicalTrials.gov

BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 5, 2021

Study Completion Date

January 5, 2021

Conditions
Hypertension
Interventions
DRUG

Bisoprolol 2.5 mg

Bisoprolol 2.5 mg will be given once daily

DRUG

Placebo

Placebo tablets will be given once daily for 2 weeks during the run-in period.

Trial Locations (1)

Unknown

Brian Tomlinson, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT02398929 - BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) | Biotech Hunter | Biotech Hunter